Page 11 of 12
Rapid development of a DNA vaccine for Zika virus
2016 | Dowd, K https://pubmed.ncbi.nlm.nih.gov/27708058/
Tags: Arboviruses, DNA, Non-Human Primate, Stratis, Zika
October 14, 2016
PharmaJet® and Vaccibody collaborate on HPV vaccine development
GOLDEN, Colo. — Oct. 25, 2016 — PharmaJet today announced a collaboration with Vaccibody AS to provide needle-free injection technology for the study of a vaccine to eradicate HPV. This disease is the main cause of cervical cancer affecting 530,000 women globally annually
Tags: DNA, HPV, Nucleic Acid, Stratis
October 7, 2016
PharmaJet® collaborates with World Health Organization
Golden, Co. — August 30, 2016 — PharmaJet today announced a multi-year agreement with the World Health Organization to provide PharmaJet’s Needle-free technology to be used in the global effort to eradicate polio.
The PharmaJet Tropis® Needle-free device has been proven to be safe, fast and easy-to-use with no possibility of needle re-use or needle sticks.
August 22, 2016
NIH using PharmaJet® in DNA Vaccine Clinical Trial for Zika Virus
Golden, Co. — August 3, 2016 — PharmaJet, the maker of innovative, needle-free injection technology, announced that the National Institutes of Health will use the PharmaJet Stratis® needle-free device in a DNA vaccine clinical trial for the Zika virus.
DNA vaccines are the way of the future. Unlike traditional vaccines, like for flu or measles, that contain whole viruses, DNA vaccines contain just a tiny piece of a virus’s genetic code, making them safe and easy to work with. For these vaccines to work however, it is not enough to just get into the bloodstream like a traditional injection, the DNA vaccine must get directly into the cells. For that purpose, a new delivery method was needed.
Tags: DNA, Nucleic Acid, Stratis, Zika
August 3, 2016
PharmaJet featured in global health innovator, PATH’s newsletter
To help end polio, intradermal delivery takes center stage.

June 30, 2016
Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia
2016 Clarke, E
Tags: Inactivated, Phase 1/2, Polio, Stratis, Tropis, Tropis/Stratis
June 27, 2016
Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates
2016 Strouts, FR
Tags: Arboviruses, Dengue, Live Attenuated, Non-Human Primate, Stratis, Tropis, Tropis/Stratis
May 23, 2016
Needle-free jet injector intradermal delivery of fractional dose inactivated poliovirus vaccine: Association between injection quality and immunogenicity
2013 Resik, S
Tags: Inactivated, Phase 3/4, Polio, Tropis
October 26, 2015
PharmaJet featured in US News and World Report
4 Options for Patients Afraid of Needles

June 11, 2015
PharmaJet Featured in InnovatioNews
PharmaJet: Consumers express high satisfaction with needle-free flu shots

March 9, 2015
Immunogenicity and safety of measles–mumps–rubella vaccine delivered by disposable-syringe jet injector in healthy Brazilian infants: A randomized non-inferiority study
2013 de Menezes Martins, R
Tags: Live Attenuated, MMR, Other Viruses, Stratis
March 1, 2015
Health Care Providers Report Ease of Use, and Preference for the PharmaJet Needle-Free Injector
GOLDEN, Colo. – March 17, 2015 – PharmaJet, the maker of innovative needle-free technology, today announced survey data revealing that healthcare providers (HCPs) would recommend the needle-free injector to colleagues and believed that the use of such a device had the capacity to increase vaccination compliance.
February 19, 2015
Survey Reveals Consumer Preference for the PharmaJet Needle-Free Flu Shot
GOLDEN, Colo. – February 26, 2015– Today, PharmaJet, the maker of innovative, needle-free injector technology, announced the release of survey data demonstrating consumer satisfaction with the PharmaJet Needle-Free Injector for seasonal flu vaccinations.
Patient Preference Survey – Stratis
Early in the 2014-2015 flu season, nearly 1,500 patients received a flu shot with the PharmaJet Needle-Free Injector at select retail pharmacies, a university flu shot event, a public health flu symposium, and a government research organization.

February 13, 2015
Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: A randomized controlled trial in Cuba
2013 Resik, S
Tags: Inactivated, Polio, Tropis
January 3, 2015
Clinical Findings Published in The Lancet Support Administration of Flu Vaccine with PharmaJet’s Needle-Free Injector
GOLDEN, Colo. – September 30, 2014 – A clinical study published in the August 23, 2014 issue of The Lancet demonstrated that delivery of AFLURIA® (Influenza Vaccine) with the PharmaJet Needle-Free Injector compared favorably to traditional needle and syringe delivery. The U.S. Food and Drug Administration (FDA) recently approved the Stratis® 0.5mL Needle-Free Jet Injector…
September 8, 2014
PharmaJet Featured In InnovatioNews
PharmaJet gets first FDA approval to use needle-free injection technology for flu shots

August 20, 2014
FDA Approves Use of Afluria®, Influenza Vaccine with PharmaJet’s Needle-Free Injector
KING OF PRUSSIA, Penn. / GOLDEN, Colo. – August 19, 2014 – PharmaJet® Inc., the developer of a needle-free injection technology to administer medications and vaccines to patients, and bioCSL Inc., the maker of AFLURIA® (Influenza Vaccine) today announced the U.S. Food and Drug Administration (FDA) has approved the PharmaJet Stratis® 0.5mL Needle-Free Jet Injector…
August 18, 2014
Page 11 of 12



